| HOME >> MEDICINE >> TECHNOLOGY |
Figure 11: New launches forecasting methodology – Illustrative example, step 2: Potential generic sales of Brand X 32
Figure 12: New launches forecasting methodology – Illustrative example, step 3: Total generic sales of Brand X 33
Figure 13: New launches forecasting methodology – Illustrative example, step 4: Generic sales company split 34
Figure 14: Zoloft and sertraline generics as a percentage of pre-expiry Zoloft sales, US, 2005–09 35
Figure 15: Global generics market, sales ($m) and growth rate (%), 2005–15 37
Figure 16: Global generics market, sales ($m) and growth rate (%), 2005–09 39
Figure 17: Global generics market, sales ($m) and growth rate (%), 2009–15 41
Figure 18: Global generics market, marketed and new launch products ($m), 2005–15 44
Figure 19: Annual sales growth from marketed and new launch products ($m), 2009–15 45
Figure 20: Global generics market by region ($m), 2005–15 46
Figure 21: Absolute sales growth by region ($m), 2005–15 47
Figure 22: Absolute growth by region ($m), 2009–15 51
Figure 23: Global generics market by therapy area ($m), 2009–15 52
Figure 24: Absolute sales growth by therapy area ($m), 2009–15 54
Figure 25: Absolute sales growth by therapy area ($m), 2009–15 57
Figure 26: Global generics market by formulation ($m), 2005–15 59
Figure 27: Absolute sales growth by formulation ($m), 2009–15 61
Figure 28: Absolute sales growth by formulation ($m), 2009–15 62
Figure 29: Global generics market by company ($m), 2005–15 64
Figure 30: Teva global generic sales ($m) and growth rate (%), 2009–15 66
Figure 31: Teva global generic sales ($m) marketed and pipeline 2009–15 67
Figure 32: Teva global generic sales by therapy area ($m) 2009–
'/>"/>
| SOURCE Reportlinker Copyright©2010 PR Newswire. All rights reserved |